Marie Rosenthal, MS


Hematology Pipeline: Baby Steps After a Giant Leap

June 21st 2012

A closer look at the hematology pipeline where there are multiple promising studies in progress for hematologic malignancies, including lymphoma, leukemia, and multiple myeloma.

The Changing World of Oncology Practice

June 18th 2012

Economic pressures are forcing many oncologists to leave small private practices for larger institutional organizations.

'Episode-Based Payment' Could Rein in US Oncology Drug Costs

May 1st 2012

With the recent consideration of the 2010 Affordable Care Act by the US Supreme Court, the rising costs of healthcare have appeared, once again, on our radar screens.

Breakthroughs in Targeted Therapies Not Applicable if Not Cost-Effective

April 20th 2012

Before the oncology treatment paradigm can move from a one-size-fits-all model to true personalized medicine, the medical establishment must find a cost-effective way to identify biomarkers.

The Big Squeeze: How to Handle Higher Costs, Shrinking Reimbursements, and Regulations That Endanger Your Practice

April 13th 2012

Shrinking reimbursements and higher healthcare costs are making it difficult for community oncologists to stay in practice.

Examining Crizotinib's Potential Uses

March 29th 2012

The development of crizotinib has helped crystallize a relatively rare molecular subset of NSCLC and holds the potential for wider use in treating patients with the disease.

Melanoma Breakthroughs Among Top 2011 Cancer Advances

January 31st 2012

Two novel treatments for advanced melanoma, ipilimumab (Yervoy) and vemurafenib (Zelboraf), were among the top breakthroughs in cancer research in 2011.

Mouth Care Systems Alleviate Xerostomia After Radiotherapy

January 31st 2012

Radiotherapy often results in the loss of some salivary gland function, causing hyposalivation and xerostomia.

Denosumab Delays Onset of Metastases in Castration-Resistant Prostate Cancer

October 18th 2011

Inhibiting the RANKL protein, which is involved in bone metabolism, can delay the onset of the bone metastases in men with castration-resistant prostate cancer.